The Brazilian Academy of Neurology (ABN) issued a statement highlighting the absence of scientific publications that prove the safety and efficacy of poly-L-lysine when used for spinal cord injuries in humans. They emphasized the importance of adhering to a rigorous treatment approval process, which requires new therapies to pass through phases 1 to 3 of clinical trials before obtaining medical prescription permission. This stance underlines a focus on patient safety and the necessity of rigorous scientific evidence in medical treatments.

Additionally, the ABN noted that any new therapies should only be utilized within strictly regulated clinical trial protocols that have received ethical approval in accordance with Brazilian law. This approach is meant to ensure that any innovative therapeutic strategies are subjected to thorough scientific scrutiny to validate their effectiveness and safety for those suffering from spinal injuries. The ABN’s recommendations aim to establish a clear standard for the application of novel medical treatments, especially in complex health conditions like spinal cord injury.

On the same day, the Brazilian Society of Neurology echoed these sentiments, stressing that spinal cord injuries represent a multifaceted health issue that requires a multidisciplinary management approach grounded in established protocols and solid scientific evidence. They acknowledged the ongoing and promising research in this field, while underscoring the importance of caution and ethical standards in the deployment of new therapies, thus reinforcing a commitment to responsible medical practice.